113 related articles for article (PubMed ID: 3579325)
1. [Preclinical evaluation of a new camptothecin derivative, CPT-11, on the subrenal capsule assay].
Wang Y; Inoue K; Shibata H; Itoh Y; Chen SC; Ogawa M
Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 1):1264-7. PubMed ID: 3579325
[TBL] [Abstract][Full Text] [Related]
2. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance.
Kanzawa F; Sugimoto Y; Minato K; Kasahara K; Bungo M; Nakagawa K; Fujiwara Y; Liu LF; Saijo N
Cancer Res; 1990 Sep; 50(18):5919-24. PubMed ID: 2168285
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of CPT-11 and its active metabolite SN-38.
Lavelle F; Bissery MC; André S; Roquet F; Riou JF
Semin Oncol; 1996 Feb; 23(1 Suppl 3):11-20. PubMed ID: 8633248
[TBL] [Abstract][Full Text] [Related]
4. [Subrenal capsule assay--an experimental study and clinical application to chemosensitivity tests].
Inoue K; Wang Y; Shibata H; Ueno K; Itoh Y; Tada A; Wada T; Mukaiyama T; Mitsui I; Ogawa M
Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 2):1629-35. PubMed ID: 3592706
[TBL] [Abstract][Full Text] [Related]
5. Camptothecin analogues with enhanced antitumor activity at acidic pH.
Adams DJ; Dewhirst MW; Flowers JL; Gamcsik MP; Colvin OM; Manikumar G; Wani MC; Wall ME
Cancer Chemother Pharmacol; 2000; 46(4):263-71. PubMed ID: 11052623
[TBL] [Abstract][Full Text] [Related]
6. Chemosensitivity testing of irinotecan (CPT-11) in ovarian and endometrial carcinomas: a comparison with cisplatin.
Koshiyama M; Fujii H; Kinezaki M; Ohgi S; Konishi M; Hidetaka N; Hayashi M; Yoshida M
Anticancer Res; 2000; 20(3A):1353-8. PubMed ID: 10928043
[TBL] [Abstract][Full Text] [Related]
7. [Subrenal capsule assay for chemosensitivity testing].
Kusuyama T; Fujita M; Shimozuma K; Orikasa H; Usugane M; Taguchi T
Gan To Kagaku Ryoho; 1987 Apr; 14(4):1143-9. PubMed ID: 3105468
[TBL] [Abstract][Full Text] [Related]
8. Establishment of a CPT-11-resistant human ovarian cancer cell line.
Kijima T; Kubota N; Nishio K
Anticancer Res; 1994; 14(3A):799-803. PubMed ID: 8074481
[TBL] [Abstract][Full Text] [Related]
9. Camptothecin analogs in malignant gliomas: comparative analysis and characterization.
Sampath P; Amundson E; Wall ME; Tyler BM; Wani MC; Alderson LM; Colvin M; Brem H; Weingart JD
J Neurosurg; 2003 Mar; 98(3):570-7. PubMed ID: 12650430
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of clinical responses in comparison with the results of the chemosensitivity test by subrenal capsule assay].
Inoue K; Wang Y; Itoh Y; Shibata H; Chen SC; Ogawa M
Gan To Kagaku Ryoho; 1987 Jul; 14(7):2305-9. PubMed ID: 3606150
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of poly(ethylene glycol)-camptothecin conjugate: the inhibition of tumor growth in vivo.
Yu D; Peng P; Dharap SS; Wang Y; Mehlig M; Chandna P; Zhao H; Filpula D; Yang K; Borowski V; Borchard G; Zhang Z; Minko T
J Control Release; 2005 Dec; 110(1):90-102. PubMed ID: 16271793
[TBL] [Abstract][Full Text] [Related]
12. [Chemotherapy testing for human ovarian cancer using in vitro colony assay].
Inoue K
Gan To Kagaku Ryoho; 1985 Aug; 12(8):1593-8. PubMed ID: 2411225
[TBL] [Abstract][Full Text] [Related]
13. Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units.
Shimada Y; Rothenberg M; Hilsenbeck SG; Burris HA; Degen D; Von Hoff DD
Anticancer Drugs; 1994 Apr; 5(2):202-6. PubMed ID: 8049503
[TBL] [Abstract][Full Text] [Related]
14. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody.
Sugimoto Y; Tsukahara S; Oh-hara T; Isoe T; Tsuruo T
Cancer Res; 1990 Nov; 50(21):6925-30. PubMed ID: 2170010
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of chemosensitivity against a human breast cancer xenograft (MX-1) with the subrenal capsule assay in BDF1 mice].
Inoue K; Wang Y; Tada A; Ueno K; Kojima K; Ogawa M
Gan To Kagaku Ryoho; 1985 Aug; 12(8):1644-50. PubMed ID: 4026333
[TBL] [Abstract][Full Text] [Related]
16. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.
Minko T; Paranjpe PV; Qiu B; Lalloo A; Won R; Stein S; Sinko PJ
Cancer Chemother Pharmacol; 2002 Aug; 50(2):143-50. PubMed ID: 12172980
[TBL] [Abstract][Full Text] [Related]
17. [Experimental and clinical studies on chemosensitivity tests of anticancer agents by human tumor clonogenic assay].
Hirabayashi N
Nihon Geka Gakkai Zasshi; 1986 Aug; 87(8):834-45. PubMed ID: 3092023
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effect of CPT-11, a new derivative of camptothecin, against human prostate cancer (PC-3) in vitro and prostate rat tumor (AT-3) in vivo.
Lievano G; Mirochnik Y; Rubenstein M; Shaw M; Guinan P
Methods Find Exp Clin Pharmacol; 1996 Dec; 18(10):659-62. PubMed ID: 9121221
[TBL] [Abstract][Full Text] [Related]
19. [Combination cancer chemotherapy using a DNA topoisomerase inhibitor CPT-11, as a core agent--the in vitro evaluation].
Oguro M; Seki Y
Gan To Kagaku Ryoho; 1991 Aug; 18(10):1556-61. PubMed ID: 1651682
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of epidermal growth factor receptor-overexpressing cancer cells by camptothecin, 20-(N,N-diethyl) glycinate.
Konkimalla VB; Efferth T
Biochem Pharmacol; 2010 Jul; 80(1):39-49. PubMed ID: 20206609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
